fda glp-1 compounding warning september 2025 Drug Recalls and Warnings: Illegal Sales and Misleading Marketing by Novo Nordisk and Eli Lilly America's Poison Centers - GLP-1

AOD 9604 best clinical result was approximately 2.8kg of additional fat loss over 12 weeks, and the larger confirmatory trial (OPTIONS study, 536 subjects, 24 weeks) failed to show statistically significant weight loss compared to placebo

Week 8: Ketosis should be established if carb restriction has been maintained

Patients with Alzheimers disease who received GLP-1s had 50% (!) less shrinkage in several parts of the brain related to memory, learning, language and decision-making compared to controls

It has the largest rotation surface area and a consistent subcutaneous fat layer

Foundayo (orforglipron) is a once-daily weight-loss pill manufactured by Eli Lilly that received FDA approval just this past April 1, 2026